pis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Way to go - I just got out of CGCP at .37 (got in at .28 and .30)!
Looks like insiders have too much control:
OTC BB:BCTI
Ownership:
· Insider and 5%+ Owners: 52%
· Institutional: 2% (4% of float)
(4 institutions)
I hope it is nothing serious - send her my regards!
That's funny, I thought I posted it directly to bb, but your right, it could have been directed at a lot of other stocks mentioned here!
Just saw that arabian! Nice way to start the morning!
PGO - what's everyone's thought on this one? Is it worth getting in on chances of them getting the necessary financing?
Good luck and make sure they don't try that 1-for-25,000 reverse stock split again!
I wouldn't touch that POS with a ten foot pole - but good luck with it and keep your eyes on it.
CGCP - got more today at .28
AKLM - could you guys believe this trading today - fifteen cent loss - and it is coming back after the dive it took in after hours and premarket.
I'm holding tight for now - like the last two news releases!
AKLM - .82 X .83
Yes. The secondary works - very slow. Here is what I was told regarding this:
>>>The secondary connection will allow you to use the faster bandwith. Be careful of the primary connection. This is used to make your computer a server, you have to allow ports in the settings section, you will have to allow your firewall to let these and if you have a router also have to configure that. It is not realy safe to use the primary connection until you understand what is happening.<<<
Castle,
I figured out why I can't use the primary connection. I have my two computers hooked up via a Linksys router. The router has a firewall. When I try to connect at primary I get the "no TCP/UDP port for incoming and outgoing packets". The firewall is not permitting it. I guess I could look into changing the settings on the router, but I want to first find out how safe/unsafe this is. Do you have a firewall?
FTGX - glad I got out of that one:
FiberNet Converts Additional Debt for Equity
/FROM PR NEWSWIRE NEW YORK 800-776-8090/
TO BUSINESS AND TECHNOLOGY EDITORS:
FiberNet Converts Additional Debt for Equity
- Further Strengthens Its Financial Position by Deleveraging and Raising
Additional Equity -
NEW YORK, Jan. 13 /PRNewswire-FirstCall/ --
FiberNet Telecom Group, Inc. (Nasdaq: FTGX), a leading provider of
metropolitan optical connectivity, announced today it has completed another
series of transactions to deleverage its balance sheet and strengthen its
financial position. The Company converted $13.4 million of senior secured
indebtedness into 138.5 million shares of common stock and raised an
additional $3.5 million of new equity capital in a private offering by issuing
29.2 million shares of common stock and warrants to purchase 56.9 million
shares of common stock. The warrants have an exercise price of $0.12 per
share and a term of five years.
As a result of these transactions, the Company has $21.7 million of
indebtedness outstanding under its senior secured credit facility, a reduction
of $74.5 million from its peak of $96.2 million in the fourth quarter of 2002.
In addition, the Company has approximately 1.0 billion shares of common stock
outstanding, or approximately 1.2 billion shares of common stock outstanding
on a fully diluted basis, assuming the exercise of all outstanding options and
warrants. The remaining three lenders under the Company's senior secured
credit facility now own approximately 30% of the outstanding shares of the
Company's common stock.
For additional information, including specific details on each transaction
and the availability to the Company of the additional capital raised, please
refer to the Company's Form 8-K to be filed with the Securities and Exchange
Commission, with respect to these transactions.
Michael S. Liss, President and CEO of FiberNet, said, "FiberNet has
accomplished a major achievement in the last few months by reducing the
outstanding indebtedness under its credit facility by 77%. We are now
well-capitalized and optimistic about strategic opportunities in the new year
and the potential for renewed organic growth."
About FiberNet
FiberNet Telecom Group, Inc. enables carriers to connect directly with one
another with unprecedented speed and simplicity over its 100% fiber optic
networks. FiberNet manages high-density short-haul networks between carrier
hubs within major metropolitan areas. By using FiberNet's next-generation
infrastructure, carriers can quickly and efficiently deliver the full
potential of their high bandwidth data, voice and video services directly to
their customers.
FiberNet has lit multiple strands of fiber on a redundant and diversely
routed SONET ring and IP architecture throughout New York City. In addition,
the Company also provides services in Chicago and Los Angeles. FiberNet sets
a new standard for the fastest local loop delivery and connectivity in carrier
hubs and Class A commercial buildings, at speeds up to OC-192 SONET and
Gigabit Ethernet. For more information on FiberNet, please visit the
Company's website at http://www.ftgx.com .
Various remarks that we may make about the Company's future expectations,
plans and prospects constitute forward-looking statements for purposes of the
safe harbor provisions under The Private Securities Litigation Reform Act of
1995. Such remarks are valid only as of today, and we disclaim any obligation
to update this information. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various important
factors, including those discussed in the Company's most recent Annual Report
on Form 10-K, which is on file with the Securities and Exchange Commission.
SOURCE FiberNet Telecom Group, Inc.
/CONTACT: Michael S. Liss, President and Chief Executive Officer,FiberNet
Telecom Group, Inc., +1-212-405-6200/
/Web site: http://www.ftgx.com /
Jan-13-2003 13:56 GMT
Symbols:
US;FTGX
Source PRN PR Newswire
Categories:
NWR/NY NWI/CPR NWI/TLS NWS/RCN MST/R/US/NY MST/I/CPM MST/I/TEL
MST/S/FNC
AKLM - looking strong in PM - earnings day!
CGO - Airline of the Year:
http://www.air-cargo-news.com/
When you say the "default connection", which were you referring to, the secondary or primary?
Castle,
I have WinMX and burn what I download onto cd's and don't have an mp3 player. Maybe because I am first saving them on my hard drive, and then burning them to a cd?
I had Kazaa, but it has spyware and I was getting "unhandled errors" until I deleted the entire program. I haven't had any problems like that with WinMX - they don't use spyware. What I would like to know from you or anyone who uses WinMX - how do you have the connection setup? I have a dsl connection, but for some reason I can only toggle the first selection: Make a secondary connection. If I try to toggle "make a primary connection", I can't. Someone mentioned to me that using the "primary connection" is unsafe and I'm better off leaving it on "secondary". Can anyone explain?
DB are the bank lenders? That is a bit strange - they obviously are basing it on the fact that they defaulted, but if they agreed to amend loan agreements and to waive the default, they must have some faith in them, no?
Oh, most Great Karnak, what do you foresee for tomorrow! LOL
Did you see this:
Reuters
S&P comments on Atlas Air Inc.
Thursday January 9, 1:19 pm ET
(The following statement was released by the ratings agency)
NEW YORK, Jan 9 - Atlas Air Inc. (B-/Watch Neg./--), a wholly owned subsidiary of Atlas Air Worldwide Holdings Inc. (NYSE:CGO - News; B/ Watch Neg./--), announced on Jan. 8, 2003, that it had entered into an agreement with its bank lenders to amend loan agreements and waive certain events of default. While the announcement is a positive development, Standard & Poor's Ratings Services said its ratings on both entities remain on CreditWatch with negative implications due to continuing concerns over near-term liquidity. The bank lenders have waived covenant compliance through the quarter ending March 31, 2003, and have deferred and reduced the amount of scheduled prepayment. Atlas expects to discuss covenant levels for the balance of 2003 with the bank group later this quarter. On Oct. 16, 2002, Atlas announced that it was initiating a reaudit of its financial results for 2000 and 2001, following a determination that certain adjustments must be made to prior-year results. As a result of the reaudit, the company delayed the filing of its third-quarter 2002 Form 10-Q, which created the event of default. The reaudit is expected to be completed in early 2003.
I have two of those... SBC and JPM - almost had a heart attack the other day when it got halted! LOL
I just got back - my boss popped in for a cup of coffee. Looks like it is doing exactly like you guessed! What else does your crystal ball say? LOL
Looking good - hope it holds.
IDNW - early morning volume - looks good right now!
That WAS very strange the way it opened.
I was just going to pm you - I'm getting the same bad vibes!
If it spikes hard I'll unload half and keep the rest - I think! LOL - I guess I really won't know what I will do until I see what happens today.
How far will this take it - do you think it has a chance of seeing .50 today or is that pushing it?
I'd much rather see it during mkt hours, but what the hay.
True, but take a look at all their other pr's - of the last 12, two were released during market hours and the rest were in after hours!
CGCP -news:
New Clinical Data Demonstrates Long Term Efficacy of CardioGenesis TMR; Should D
/FROM PR NEWSWIRE LOS ANGELES 213-626-5500/
TO BUSINESS AND MEDICAL EDITORS:
New Clinical Data Demonstrates Long Term Efficacy of CardioGenesis TMR;
Should Dispel Fears of Placebo Effect
After Five Years, 96% of Surviving Patients Continued to Show Improvement
of at Least Two Angina Classes With Trend Toward Improved Survival Over
Medically Managed Patients
FOOTHILL RANCH, Calif., Jan. 9 /PRNewswire-FirstCall/ --
CardioGenesis Corporation (Nasdaq: CGCP), the market leader in
angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous
Myocardial Revascularization (PMR), today announced that the first long-term
follow up data of a randomized, controlled TMR clinical trial show that
96 percent of surviving patients exhibited an improvement (reduction in pain)
of at least two angina classes five years after their initial TMR treatment.
The data also showed that incremental reductions in pain occurred after one
year.
Keith B. Allen, M.D., a cardiothoracic surgeon at St. Vincent's Hospital
in Indianapolis, one of the two centers that have completed long-term follow
up of the CardioGenesis Ho:YAG TMR versus Medical Management Trial, presented
the five-year follow-up data in December at the Global Angiogenesis Workshop
in New York, a scientific meeting of leading angiogenesis researchers from
around the world.
The data included all 94 randomized patients enrolled in the trial
conducted at St.Vincent's and Louisville-based Jewish Hospital, two centers
that were part of the pivotal clinical trial that served as the basis of the
FDA approval of the CardioGenesis Ho:YAG system in March 1999. The pivotal
clinical trial was conducted at 18 centers and the 12-month results of the
that trial, which were published in the New England Journal of Medicine in
October 1999, showed that 76 percent of the patients treated with TMR improved
at least two angina classes from their baseline. Five-year follow-up was
conducted on all patients in the initial study at these two prominent
cardiovascular centers and included a blinded angina assessment, which
compared the medically managed group of patients with the TMR-treated group.
CardioGenesis will continue to collect long term follow-up data from other
centers included in the pivotal trial.
Dr. Allen said the enduring relief from angina pain demonstrated by the
new data should help dispel any lingering fears that TMR's benefits are
transitory or due to a placebo effect.
"This is clear evidence of the long lasting efficacy of TMR as a means of
relieving the crippling pain of angina," Dr. Allen said. "I believe this
dramatic improvement over time, increasing from 12 months to five years,
should help support the awareness of TMR as a significant clinical tool and
support a widespread adoption of the procedure for patients suffering from
late stage cardiovascular disease."
Other highlights of the long term follow-up data include:
-- Mean angina class in the TMR treated patients consistently improved
from 4.0 at baseline, to 1.5 (the larger number indicates more severe
pain) at one year, and 1.1 at five years, a statistically significant
improvement in angina status.
-- Survival at 5 years in the TMR group was 57% compared to 44% in the
medical treatment group.
Dr. Allen noted that the study provides for the first time five-year
follow up results on a prospective, randomized TMR clinical trial. Previously
reported five-year results for the CO2 TMR technology have been on a treated
patient series only, with no follow up provided for the control group, and
those results presented have been censored for patients who died or received
additional revascularization procedures.
Robert D. Dowling, M.D., the principal investigator of the Ho:YAG TMR
trial at Jewish Hospital, said the long-term persistent improvement
demonstrated in the study provides important information for the
cardiothoracic surgeon and referring physician.
"Undergoing a surgical procedure includes inherent risks, and the long
term persistent benefit of TMR demonstrated in this study provides significant
validating data as to why TMR is an important and highly effective late stage
coronary artery disease (CAD) disease treatment option," Dr. Dowling said.
"These 5 year results demonstrate the robust effectiveness of TMR with the
CardioGenesis Ho:YAG system, providing an impressive level of scientific and
clinical evidence supporting the use of this laser revascularization therapy."
Michael J. Mack, M.D. of Medical City Hospital in Dallas, who has utilized
TMR since the approval of the CardioGenesis Ho:YAG system in 1999, said the
results will support increased use of the system in the future. He
characterized this evidence of the long-term benefit of TMR with the
CardioGenesis Ho:YAG system as "A significant step forward in validating TMR
as a relevant and increasingly important clinical tool in the treatment of
late stage CAD. The cardiothoracic surgeon faces more complex clinical and
technical challenges as patients suffering from CAD are being referred to
surgery later in the progression of the disease. TMR is an innovative and
effective tool to help the surgeon achieve optimal patient outcomes in the
treatment of late stage disease."
CardioGenesis Chairman and CEO Michael J. Quinn said the Company is
committed to continuing the important research into understanding the
long-term effects of TMR and PMR, a catheter-based version of the treatment.
TMR and PMR are the only late stage therapy options for this patient group
that have been validated with a series of prospective, randomized clinical
trials, Quinn said.
"The quality and magnitude of these long-term clinical results provide
overwhelming evidence supporting the use of TMR and effectively dispels the
conjecture that the benefits may be transitory or a placebo," Quinn said.
"This data represents the first comprehensive report on the long term effects
of TMR from a prospective, randomized study. CardioGenesis is again providing
important scientific data to the medical community, showing substantial
scientific evidence supporting the clinical application of our Ho:YAG laser
technology -- which has not been made available to date for CO2 TMR or other
late stage therapeutic options. This study is clearly one of the most
important clinical developments in the Company's history as it provides us a
new set of important tools to use in our campaign to expand the use of TMR."
Quinn added that the company is focused on growing the TMR business. "As
the market leader, it is up to CardioGenesis to drive the awareness and
adoption of TMR," Quinn remarked. "We are accomplishing this through
important new studies that will provide patients and physicians with the data
to make informed treatment decisions. We are encouraged at the progress we
have made in 2002, and are working closely with clinicians and researchers to
provide more important new research regarding the CardioGenesis Ho: YAG TMR
system to the market going forward."
TMR and PMR are related procedures in which physicians use lasers to
create small channels in the heart muscle to trigger the mechanisms of
angiogenesis, or the creation of new blood vessels in the heart. The FDA
approved TMR, a surgical version of the procedure, in 1999. PMR is a
catheter-based version of the procedure that is not yet cleared by the FDA in
the U.S. but is CE approved. The Company is continuing to move ahead in its
efforts to gain FDA clearance this year to market PMR in the U.S. and extend
the benefits of that minimally invasive procedure well beyond the
2,000 patients who have already been successfully treated with PMR.
About CardioGenesis Corporation
CardioGenesis is a medical device company specializing in the treatment of
cardiovascular disease and is the leader in products that stimulate cardiac
angiogenesis. The Company's market leading Holmium: YAG laser system and
disposable fiber-optic accessories are used to perform a FDA-cleared surgical
procedure known as transmyocardial revascularization (TMR) to treat patients
suffering from angina. The CardioGenesis TMR procedure, which is marketed in
the U.S. and around the world, has been shown to reduce angina and improve the
quality of life in patients with coronary artery disease. The Company's
minimally invasive PMR procedure is currently being marketed in Europe and
other international markets.
For more information on the Company and its products, please visit the
CardioGenesis web site at http://www.cardiogenesis.com . For investor
relations information, visit the CardioGenesis pages in the "Client" section
of the Allen & Caron Inc web site at www.allencaron.com .
Any forward-looking statements in this news release related to the
Company's sales, profitability, the adoption of its technology and products
and FDA clearances are based on current expectations and beliefs and are
subject to numerous risks and uncertainties that could cause actual results to
differ materially. Other factors that could cause CardioGenesis' actual
results to differ materially are discussed in the "Risk Factors" section of
the Company's Annual Report on Form 10-K for the year ended December 31, 2001,
its Quarterly Report on Form 10-Q for the third quarter ended September 30,
2002, and the Company's other recent SEC filings. The Company disclaims any
obligation to update any forward-looking statements as a result of
developments occurring after the date of this press release.
For further information, please contact: investors, Mike Mason,
+1-212-691-8087, michaelm@allencaron.com, or media, Len Hall,
+1-949-474-4300, len@allencaron.com, both of Allen & Caron Inc, for
CardioGenesis Corporation; or Darrell Eckstein, President of CardioGenesis
Corporation, +1-714-649-5000.
SOURCE CardioGenesis Corporation
/CONTACT: investors, Mike Mason, +1-212-691-8087,michaelm@allencaron.com, or
media, Len Hall, +1-949-474-4300,len@allencaron.com, both of Allen & Caron Inc,
for CardioGenesis Corporation;or Darrell Eckstein, President of CardioGenesis
Corporation, +1-714-649-5000/
/Web site: http://www.cardiogenesis.com /
Jan-09-2003 12:32 GMT
Symbols:
US;CGCP
Source PRN PR Newswire
Categories:
NWR/CA NWI/BIO NWI/MTC MST/R/US/CA MST/I/BTC MST/I/DRG
CGO:
Atlas Air Obtains Waiver, Eliminates Default
Wednesday January 8, 5:25 pm ET
PURCHASE, N.Y.--(BUSINESS WIRE)--Jan. 8, 2003--Pursuant to an 8K filing today, Atlas Air, Inc., a wholly owned subsidiary of Atlas Air Worldwide Holdings (NYSE: CGO - News), announced that it has entered into an amendment and waiver with its bank lenders to amend certain loan agreements and to waive certain events of default arising under the loan agreements and related aircraft leases.
Compliance with various financial covenants has also been waived through March 31, 2003. The Company expects to discuss financial covenant levels for the balance of 2003 with its bank lenders later in the first quarter.
Atlas Air Worldwide Holdings, Inc. is the parent company of Atlas Air, Inc. ("the Company") and of Polar Air Cargo, Inc. Atlas Air offers its customers a complete line of freighter services, specializing in ACMI (Aircraft, Crew, Maintenance, and Insurance) contracts, utilizing its fleet of B747 aircraft. Polar's fleet of Boeing 747 freighter aircraft specializes in time-definite, cost-effective, airport-to-airport scheduled airfreight service.
--------------------------------------------------------------------------------
Contact:
Atlas Air, Inc.
Media
Rachel Berry, 914/701-8400
or
Investor
Jason Grant, 914/701-8402
--------------------------------------------------------------------------------
Source: Atlas Air, Inc.
Lookin very good - take a look at level II on the ask.
Check out premarket for STOR.
??? You picked up TSSM to protect yourself from previous r/s losses? Larry, you sound like a "wild and crazy kind of guy"! LOL
Do you mean "I" meaning you are done buying, or did you mean to say "it" may be finally done meaning the s-8's?
Have to admit, I broke down and picked up some TSSM at .0005 - S-8's gotta dry up some time, right??LOL
EDSN - has that been one of the best trading stocks or what? By the way - check out TSSM.
CGO - check out the volume - it has exceeded yesterday's entire volume in the first 45 minutes.